ARWR ARROWHEAD PHARMACEUTICALS, INC. Insider Trading

CFO Apel sells 13.1K shares at $71.35 avg, retains 162.9K; stock near 52-week peak at $73.91

Apel, Arrowhead Pharmaceuticals' CFO, executed 3 separate sales totaling 13,095 shares for $934,285.13, reducing holdings by 7.4% to 162.9K shares. The trades were executed at a blended average price of $71.35 across April 22, 2026, occurring when the stock is trading at $73.91, just 0.7% below its 52-week high of $74.40 and up 21.6% over the past 30 days. While the company has returned to profitability in its latest quarter with $30.8M net income on $264.0M revenue and demonstrated strong annual revenue growth of 23258.2%, the broader context shows the company had been unprofitable over its most recent full fiscal year. The CFO retains substantial holdings post-transaction, and the sales represent a modest portfolio reduction rather than a material exit.

CMO Hamilton James sells 10,000 ARWR shares at $64.19; stock now at $60.67, down 6.0% in 30 days

Hamilton James C, Chief Medical Officer, sold 10,000 shares of ARROWHEAD PHARMACEUTICALS at $64.19 on 2026-03-05, reducing his holdings by 4.0% to 236,958 shares. The stock has declined 6.0% over the subsequent 30 days and currently trades at $60.67, down 16.9% from its 52-week high. His cross-ticker track record shows 15 prior sells with a 90-day well-timed rate of 87.50%, indicating his sales have historically preceded stock declines, though his same-ticker history at ARWR contains five prior sales from January 2026 with mixed 30-day returns (ranging 0.1% to 11.1%) and no measurable 90-day outcomes yet. The company reported strong recent fundamentals—$264.0M quarterly revenue, $30.8M net income, and +23258.2% annual revenue growth—but the elevated P/E of 42.13 and the stock's 11.9% decline over 90 days suggest valuation or sentiment headwinds despite operational strength.

CMO Hamilton James C sells 40,164 shares for $2.5M across 7 tranches; stock +74.8% in 90 days, well above insider's cross-ticker baseline.

Hamilton James C, Chief Medical Officer, executed 7 separate sales totaling 40,164 shares for $2,534,661.46 on 2026-01-05, reducing holdings by 18.9%. The sales occurred at prices ranging from $61.24 to $68.00, with a blended average of $63.11, while the stock now trades at $63.88. At Arrowhead, his prior 5 tracked sales were well-timed 80% of the time at the 90-day mark; however, this institution remains unprofitable (net income: $-175,241,000.00 in the latest full fiscal year) despite sharp revenue growth of 23258.2%. The broader context is material: the stock has risen 74.8% over 90 days and sits only 9.8% below its 52-week high, while his cross-ticker track record shows an 87.50% well-timed rate on prior sells but a negative 90-day return average of -8.4%, indicating recent sell timing has diverged from his historical pattern. The scale of this single-day, multi-tranche liquidation—18.9% of holdings—merits examination in relation to ongoing research or commercial developments at the company.

COO Patrick O'Brien sold 49,493 shares for $3,123,349.43 across 12 transactions on 2026-01-05

Patrick O'Brien, Chief Operating Officer of Arrowhead Pharmaceuticals, executed 12 separate sales totaling 49,493 shares for $3,123,349.43 on 2026-01-05, reducing his holdings from 524,401 to 474,908 shares (a 9.4% reduction). This is significant given his prior 5 trades at ARWR, all of which were sells that proved well-timed at the 90-day mark, with 4 of 5 showing negative 90-day returns ranging from -23.2% to -47.9%; his cross-ticker track record also shows a 100.00% well-timed rate across 11 prior sales with an average 90-day return of -28.5%. The stock is trading near its 52-week high at $63.88 (just 9.8% below the $70.82 peak) and has gained 4.0% over 30 days and 74.8% over 90 days, creating a backdrop where a large insider sale from an operator with a demonstrated pattern of favorable exit timing may signal caution, though the company remains unprofitable with net income of $-175,241,000.00 over its most recent full fiscal year. Investors should note the magnitude of this multi-tranche sale and compare it against O'Brien's historical execution at this specific ticker before drawing conclusions about forward outlook.

CEO Anzalone sells 13,187 shares at $66.10 avg for $871.7K; 5th consecutive sale in 7 days

Christopher Richard Anzalone, Chief Executive Officer, executed 2 separate sales totaling 13,187 shares for $871,702.77, reducing holdings from 3.81M to 3.79M shares (-0.3%). This sale follows 4 prior sales at ARWR within the previous 7 calendar days (2025-12-19, 2025-12-22, 2025-12-29), establishing a concentrated selling pattern. The transaction prices of $65.88 and $66.39 on 2026-01-02 sit 3.2% below the current price of $63.88, though remain well above the 52-week low of $9.99 and near the upper half of the 52-week range. The company's fundamentals show significant distress: the most recent full fiscal year reported net income of $-175.2M against quarterly revenue of $27.8M, placing the firm in unprofitable territory despite 90-day stock momentum of +74.8%. Taken together, the CEO's repeated sales in consecutive trading windows warrant close monitoring of institutional and advisory positioning, particularly given the contradiction between recent positive price momentum and the company's sustained operating losses.

ARWR CEO Anzalone sells 51,726 shares in 2 transactions for $3,575,574.78; holds 3.81M shares post-sale

Christopher Richard Anzalone, CEO of Arrowhead Pharmaceuticals, executed 2 separate sales on 2025-12-29, offloading 51,726 shares (51.7K shares) for $3,575,574.78 at a blended average price of $69.13. His post-transaction holdings of 3.81M shares represent a -1.3% reduction from prior holdings of 3.86M shares. The sale occurs in a stock trading near its 52-week high of $70.82 and is the latest in a recent series of five ARWR sales executed across 2025-12-19 through 2025-12-22. Notably, the company reported a $-175.2M net loss in its latest quarter despite $27.8M in revenue and remains unprofitable on a full-year basis, though it shows exceptional annual revenue growth of +23258.2%. This sale warrants scrutiny given the frequency of recent transactions and the company's negative profitability backdrop.

ARWR CEO Anzalone sells 26,031 shares for $1,771,022.38 across 5 transactions Dec 19-22

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, executed 5 separate sales totaling 26,031 shares for $1,771,022.38 between December 19 and December 22, 2025, at a blended average price of $68.04. The stock has since appreciated to $69.83 (current price), representing a modest unrealized gain on the executed sales. His post-transaction holdings of 3,805,926 shares represent a 0.7% reduction in his position. The stock has appreciated 72.6% over the prior 30 days and 112.7% over the prior 90 days, positioning these sales near the 52-week high ($70.82). His cross-ticker track record shows 20 prior open-market sells with a 0.00% well-timed rate at the 90-day mark, indicating his prior sales have not positioned him ahead of subsequent price declines. At the company level, Arrowhead is unprofitable (net income of $-175,241,000.00 for the most recent full fiscal year) despite strong revenue growth of 23258.2% year-over-year, with a quarterly revenue of $27,767,000.00 and market cap of $9,483,581,435.14.

ARWR CEO Anzalone sold 85,000 shares for $5.4M on 2025-12-17 at $64.04 blended price; retains 3.83M shares.

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, executed 4 separate sales totaling 85,000 shares for $5,443,462.11 on 2025-12-17, with transaction prices ranging from $63.55 to $66.30 and a blended average price of $64.04. Post-transaction holdings of 3,831,957 shares represent a 2.2% reduction from pre-transaction levels, leaving the CEO with substantial continued ownership. The timing of these sales is notable given the stock's recent performance: the current price of $68.16 sits 3.8% below the 52-week high of $70.82, but the stock has surged 74.9% over the past 30 days and 122.1% over the past 90 days. The company's fundamentals present a mixed picture—revenue grew 23258.2% year-over-year driven by acquisitions and strategic shifts, but the business remains unprofitable with a net loss of $175,241,000.00 in the latest quarter and full-year negative net income. Across all his open-market history, Anzalone's cross-ticker track record shows 20 prior sells with an average 90-day return of +65.4% following those sales, indicating those sells were poorly timed (the stock rose after he sold), with a 0.00% well-timed rate. This pattern of selling into strength, combined with the company's ongoing unprofitability despite revenue expansion, merits investor attention.

ARWR CEO Anzalone sells 184,298 shares for $12,348,801.97 across 12 transactions; holds 3.92M shares post-sale

Christopher Richard Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, executed 12 separate sales totaling 184,298 shares for $12,348,801.97 between December 15–16, 2025, reducing his holdings by 4.5% to 3.92M shares. The sales occurred at prices ranging from $60.51 to $69.96, with a blended average of $67.00, near the 52-week high of $70.82 and well above current price of $64.66. Notably, across his 5 prior trades at ARWR, Anzalone's sells have consistently been poorly timed: all 5 were followed by positive 90-day returns (ranging from +49.2% to +76.6%), meaning the stock rose after each sale. This established pattern stands in sharp contrast to the data: a CEO selling material value at elevated prices after a 56.7% 30-day and 122.0% 90-day surge warrants attention, particularly given the company's unprofitable operations (net income $-175.2M) despite strong recent stock momentum. The sustained underperformance of his ARWR timing signals merit review of whether this represents risk management in a volatile position or market dynamics independent of fundamental valuation.

CMO Hamilton James C sold 20,000 shares of ARWR at $35.00 (700K); stock now at $36.12 after +29.9% 30d surge.

Hamilton James C, Chief Medical Officer, sold 20,000 shares at $35.00 on 2025-10-01, reducing his stake from 232.1K to 212.1K shares. The sale occurred within a 30-day surge of +29.9% and 90-day surge of +115.1%, with the stock currently trading at $36.12 near its 52-week high. Notably, his prior trades at ARWR show a 5 of 5 well-timed pattern at the 90-day mark, with negative post-sale returns (ranging -1.7% to -10.4%) across the same ticker, though the cross-ticker track record (7 prior sells) averaged -22.7% 90-day return with 100% well-timed rate. Against this backdrop, the company faces severe headwinds: revenue contracted -98.5% year-over-year to $27.8M in the latest quarter, net income was negative $-175.2M, and the company remained unprofitable over the full fiscal year. The insider's sale near the stock's 52-week high, coupled with the company's dramatic revenue collapse and persistent losses, warrants investor attention.